We studied the brightness and spectral evolution of the young eruptive star V1647 Ori during its recent outburst in the period 2004 FebruaryY2006 September. We performed a photometric follow-up in the bands V, R C , I C , J, H, and K s , as well as visible and near-IR spectroscopy. The main results derived from combining our data with those published by other authors are as follows: the brightness of V1647 Ori stayed more than 4 mag above the preoutburst level until 2005 October, when it started a rapid fading. In the high state we found a periodic component in the optical light curves with a period of 56 days. The delay between variations of the star and variations in the brightness of clumps of nearby nebulosity corresponds to an angle of 61 AE 14 between the axis of the nebula and the line of sight. The overall appearance of the infrared and optical spectra did not change in the period 2004 MarchY2005 March, although a steady decrease of H i emission-line fluxes could be observed. In 2006 May, in the quiescent phase, the He i 1.083 m line was observed in emission, contrary to its deep blueshifted absorption observed during the outburst. The J À H and H À K s color maps of the infrared nebula reveal an envelope around the star whose largest extension is about 18 00 (0.03 pc). The color distribution of the infrared nebula suggests reddening of the scattered light inside a thick circumstellar disk. Comparison of the K s and H images of McNeil's Nebula, the conical nebulosity illuminated by V1647 Ori, shows that HH 22A, the Spitzer infrared source, and the bright clump C of the nebula may be unrelated objects. We show that the observed properties of V1647 Ori could be interpreted in the framework of the thermal instability models of Bell and coworkers. V1647 Ori might belong to a new class of young eruptive stars, defined by relatively short timescales, recurrent outbursts, a modest increase in bolometric luminosity and accretion rate, and an evolutionary state earlier than that of typical EXors.
In serum-starved NIH 3T3 clone 7 fibroblasts, choline phosphate (ChoP) (0.5-1 mM) and insulin synergistically stimulate DNA synthesis. Here we report that ATP also greatly enhanced the mitogenic effects of ChoP (0.1-1 mM) both in the absence and presence of insulin; maximal potentiating effects required 50 -100 M ATP. The co-mitogenic effects of ATP were mimicked by adenosine 5-O-(3-thiotriphosphate), adenosine 5-O-(2-thiodiphosphate), ADP, and UTP, but not by AMP or adenosine, indicating the mediatory role of a purinergic P 2 receptor. Externally added ChoP acted on DNA synthesis without its detectable uptake into fibroblasts, indicating that ChoP can be a mitogen only if it is released from cells. Extracellular ATP (10 -100 M) induced extensive release of ChoP from fibroblasts. ChoP had negligible effects, even in the presence of ATP or insulin, on the activity state of p42/p44 mitogen-activated protein kinases, while in combination these agents stimulated the activity of phosphatidylinositol 3-kinase (PI 3-kinase). Expression of a dominant negative mutant of the p85 subunit of PI 3-kinase or treatments with the PI 3-kinase inhibitor wortmannin only partially (ϳ40 -50%) reduced the combined effects of ChoP, ATP, and insulin on DNA synthesis; in contrast, the pp70 S6 kinase inhibitor rapamycin almost completely inhibited these effects. ATP and insulin also potentiated, while rapamycin strongly inhibited, the mitogenic effects of sphingosine 1-phosphate (S1P). Furthermore, even maximally effective concentrations of ChoP and S1P synergistically stimulated DNA synthesis. The results indicate that in the presence of extracellular ATP and/or S1P, ChoP induces mitogenesis through an extracellular site by mechanisms involving the activation of pp70 S6 kinase and, to a lesser extent, PI 3-kinase.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.